Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLei LvQLQingyang Liu

Discussion

Loading...

Member takes

Overview

Phase 3 trial reports 98.8% overall response rate in newly diagnosed AML patients treated with venetoclax-azacitidine, indicating improved effectiveness over daunorubicin therapy.

Key Points

  • CACAG+VEN achieved 98.8% overall response rate, significantly outpacing daunorubicin's 75.3%.
  • Event-free survival was higher in the CACAG+VEN group at 80% compared to 70.1% in the DA group (P = 0.0463).
  • Patients in the CACAG+VEN group showed significantly lower rates of febrile neutropenia and grade ≥3 lung infections.
  • This trial demonstrates enhanced safety and efficacy for venetoclax-azacitidine in treating acute myeloid leukemia.

Cite This Study

Lv et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da5fhttps://doi.org/10.1182/blood-2025-3416
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026
  2. 2Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study2025
  3. 3The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia2025
  4. 4Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  5. 5Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations